Form 4: Verastem Director Karin Tollefson Receives Equity Compensation Package

Verastem, Inc. Director Karin Anna Tollefson was granted 8,333 Restricted Stock Units and 12,500 stock options on May 22, 2025, as part of her compensation under the company's equity incentive plan.

Summary

• Karin Anna Tollefson, a Director of Verastem, Inc. (VSTM), reported changes in her beneficial ownership of company securities.
• On May 22, 2025, Ms. Tollefson was granted 8,333 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Ms. Tollefson beneficially owns 16,666 shares of Common Stock.
• The RSUs will vest in twelve equal installments, with the first eleven vesting on the last day of each month from June 2025 to April 2026.
• The final RSU installment will vest on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026, contingent on her continued service as a director.
• Additionally, on May 22, 2025, Ms. Tollefson was granted 12,500 stock options with an exercise price of $7.48 per share.
• These stock options have an expiration date of May 22, 2035.
• The stock options also vest in twelve equal installments, following the same schedule as the RSUs: the first eleven from June 2025 to April 2026, and the final installment on the earlier of the day before the 2026 Annual Meeting or May 31, 2026, subject to continued directorship.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive for aligning management interests with shareholders and is a standard practice. It does not indicate any negative operational or financial news.

Positives

• The grant of equity awards (RSUs and stock options) aligns the director's interests with those of the shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• The issuance of new equity awards, particularly RSUs, can lead to a slight dilution of existing shareholder ownership upon vesting and conversion to common stock.

Risks

• The vesting of both the RSUs and stock options is contingent upon Karin Anna Tollefson's continued service as a director of Verastem, Inc. on each vesting date.

Future Outlook

The equity grants are structured to incentivize the director's continued service and align her long-term interests with the company's performance, with vesting scheduled through May 2026.

Industry Context

The granting of Restricted Stock Units and stock options to directors is a common and widely accepted practice across various industries, particularly in biotechnology and pharmaceutical sectors like Verastem, Inc., to attract, retain, and motivate key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a standard practice in the biotechnology and pharmaceutical industries, aligning with global benchmarks for corporate governance and incentive structures.
• While the specific number of units and options granted varies significantly based on company size, stage of development, and individual director responsibilities, the structure of performance-based equity awards is consistent with compensation strategies seen in comparable companies such as smaller-cap biotech firms.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of RSUs and exercise of options, but also benefit from incentivized director performance.
• Employees: No direct impact mentioned, but reflects standard compensation practices within the company.

Next Steps

• Karin Anna Tollefson's continued service as a director of Verastem, Inc. is required for the vesting of her RSUs and stock options.
• The company will continue to report future changes in beneficial ownership for insiders via Form 4 filings.

Key Dates

Recommendation

Keywords

Verastem, VSTM, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership